Mixed Reviews for New AML Drugs.
Of two new FDA-approved therapies for acute myeloid leukemia (AML), hematologists expect that the FLT3/AXL inhibitor gilteritinib will likely become an integral part of treatment. However, they think glasdegib, which targets the Sonic hedgehog pathway, may have limited utility, because it must be prescribed alongside cytarabine, an uncommon AML treatment option in the United States.